Watch and listen as Frederick L. Altice, MD, and Norah Terrault, MD, MPH, discuss current and emerging trends in the epidemiology of HCV infection in the United States with a focus on what these trends mean for strategies aimed at achieving HCV elimination.
Watch and listen as Jordan J. Feld, MD, MPH, and Natasha Martin, DPhil, discuss what makes achieving HCV elimination feasible: targeting at-risk populations, delivering multiple interventions, and personalizing interventions to optimize outcomes by risk group.
Watch and listen as Jordan J. Feld, MD, MPH, and Natasha Martin, DPhil, discuss how dramatic changes in the HCV treatment landscape have enabled high cure rates to be safely achieved across a wide range of patient populations, including those previously excluded from HCV therapy because of previous or ongoing injection drug use. Expert faculty will also discuss how improved therapies have led to the concept of HCV treatment-as-prevention among high-risk populations as a critical strategy to reduce HCV incidence and prevalence in the United States.
Watch and listen as Frederick L. Altice, MD, and Natasha Martin, DPhil, discuss the current structural, geographic, and patient-specific barriers to HCV elimination in the United States.
Watch and listen as Alain H. Litwin, MD, and Brianna L. Norton, DO, discuss the roles of primary care physicians in screening, diagnosing, treating, and referring patients infected with HCV.
Watch and listen as Jordan J. Feld, MD, MPH, and Norah Terrault, MD, MPH, discuss the evolving roles of hepatologists, gastroenterologists, and infectious disease clinicians in the current HCV treatment landscape and review important strategies that these specialists can take in moving toward the goals of HCV elimination in the United States.